Clinical Trial

Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT

Completed
View on ClinicalTrials.gov →
Summary
The objective of this observational study is to explore the long-term effects of roprastine given to promote platelet implantation in hematopoietic stem cell hemicongruent transplantation in children with thalassemia. The main questions it aimed to answer is: Is roprastine safe and effective for platelet implantation in children with thalassemia hemicongruent transplantation? Participants who have already received roprastine as part of routine medical care for hematopoietic stem cell hemicongruent transplantation in children with thalassemia will answer online survey questions about the effects of their platelet implantation within 8 weeks.
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Completed 2026-07-29
notable Enrollment reduced: 30 -> 16 participants 2026-07-29
Trial Details
NCT Number NCT07003256
Lead Sponsor Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Conditions Thalassemia in Children
Enrollment 16 participants
Start Date 2024-09-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28